(May 29, 2024, 10:20 AM EDT) -- WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals on May 28 granted a patent owner a 14-day extension of its deadline to reply to claims by Novartis Pharmaceuticals Corp. that the doctrine of collateral estoppel bars review of a decision by the Patent Trial and Appeal Board that canceled a patented form of polymorphic fingolimod hydrochloride....